Wells Fargo Maintains Overweight on GoodRx Holdings, Lowers Price Target to $3.5
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Stan Berenshteyn maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and lowers the price target from $7 to $3.5.
Wells Fargo analyst Stan Berenshteyn maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and lowers the price target from $7 to $3.5.